Vít Karásek

Mr. Vít Karásek

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VMVibeke Maniche
Vibeke Maniche
VKVít Karásek
Vít Karásek
MSMax Schmeling
Max Schmeling
JGJonathan D. Gilthorpe
Jonathan D. Gilthorpe
TFTomáš Fürst
Tomáš Fürst
PHPeter Riis Hansen
Peter Riis Hansen
Background: Preliminary reports have suggested a batch-dependent safety signal for COVID-19 vaccines. It is important to establish if these findings can be replicated. Methods: We used publicly available nationwide data from Germany spanning the first 3.5 years of the vaccination campaign to calculate weekly rates of spontaneously reported suspected adverse events (SAEs) per 1 000 administered vaccine doses. Results: SAE rates ranged between 2.2 and 22.8 per 1 000 doses and women accounted for 72% of all SAEs. Crucially, SAE rates for Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), and Vaxzevria (AstraZeneca) were very high in the initial phase of vaccination rollout and hereafter declined precipitously. For example, SAE rates in weeks 1-4 of 2021 were 8.2, 50.8, and 620.9 per 1 000 doses of Comirnaty, Spikevax, and Vaxzevria, respectively, but fell to 4.4, 11.6, and 7.4 per 1 000 doses in weeks 12-16 of 2021. Conclusions: SAE rates in Germany were highly elevated in the initial phase of COVID-19 vaccination rollout and then fell precipitously, a pattern compatible with a batch-dependent safety signal. Furthermore, there was a considerable overrepresentation of women with SAEs. These preliminary results call for more definitive studies of batch-dependent COVID-19 vaccine safety.